A 41-year-old pregnant African-American woman noticed rapid growth of her cesarean delivery skin scar beginning at 14-week gestation. Skin biopsy, which was performed at 31 weeks, revealed poorly differentiated cutaneous melanoma. At 34 weeks, she underwent repeat cesarean delivery with tumor excision, pelvic lymphadenectomy and abdominal wall reconstruction. Locally advanced disease and anatomical limitations prevented attainment of negative surgical margins. Despite adjuvant chemotherapy and radiation, she died 1 year after diagnosis. Deferring biopsy of a suspicious skin lesion during pregnancy may have delayed the diagnosis of melanoma in this case and possibly affected the long-term outcome.
Introduction
Approximately one-third of malignant melanoma in women occurs during the reproductive years, making melanoma one of the most frequently encountered malignancies during pregnancy. 1 The effects of pregnancy on the incidence of melanoma and its progression have long been debated. 1 Although the recent controlled studies have not demonstrated a greater tendency for melanomas to exhibit a more aggressive growth pattern during pregnancy, clinical and laboratory data continue to suggest that pregnancy-associated hormones may influence melanoma progression and development. [2] [3] [4] [5] According to the American College of Obstetricians and Gynecologists' Committee Opinion on Nonobstetric Surgery during Pregnancy, pregnant women should not be denied indicated emergency surgery although elective surgery may be deferred until after delivery. 6 Consequently, some physicians may consider skin biopsies to be elective and delay these procedures. As result, pregnancy may be associated with delayed diagnosis of some skin diseases. Although earlier diagnosis may not necessarily improve outcomes, earlier diagnosis may give patients the opportunity for pregnancy termination if desired.
In this report, we present the case of a pregnant AfricanAmerican woman who developed locally advanced cutaneous melanoma in a cesarean delivery skin scar. To our knowledge, this is the first report of melanoma arising from a cesarean delivery skin scar. In addition, the 19-week lag between initial symptoms presentation and definitive diagnosis, which may have impacted overall outcome, illustrates the value of performing diagnostic procedures, such as skin biopsies, during pregnancy.
Case
A 41-year-old African-American woman, gravida 2 para 1, was transferred to our institution at 33-weeks gestation for the management of a lower abdominal mass.
The patient underwent a primary cesarean delivery for nonreassuring fetal status 4 years prior. Her incision healed with a firm and nodular skin scar that clinically appeared to be a keloid. Gynecological, medical and surgical histories were unremarkable, and she had no personal or family history of skin cancer.
At B14-week gestation, she noticed a 'bump' on the left lateral aspect of her scar, which she reported to her obstetrician. This 'bump' was perceived to be an enlarging keloid, and the patient was given reassurance. A skin biopsy was not performed.
At 28-weeks gestation, exponential growth of the mass caused stretching of the skin and severe pain over the mons pubis leading to emergent evaluation at an outside institution. Physical examination revealed a 10 Â 12 cm tender and indurated mass at the left aspect of her cesarean delivery scar. Magnetic resonance imaging revealed a 10.6 Â 7 Â 6 cm heterogeneous abdominal mass involving the left lower rectus abdominus musculature and extending to the skin surface. As the mass was thought to be benign, biopsy was deferred secondary to pregnancy. The patient received oral pain medications for symptomatic relief, and was referred to her primary medical doctor for further management.
Increasing pain refractory to oral analgesics prompted admission at a second institution at 31 weeks. Fine-needle aspiration of the mass revealed a poorly differentiated spindle cell neoplasm concerning for melanoma. A course of betamethasone was administered to promote fetal lung maturity, and at 33-weeks gestation, the patient was transferred to our institution for further management.
On admission, the patient complained of severe pain at the site of the mass requiring intravenous narcotic pain medication. She reported active fetal movement, and denied vaginal bleeding, leakage of amniotic fluid and uterine contractions.
Physical examination revealed a 10 Â 10 cm tender, exophytic mass arising from the left lateral aspect of the previous pfannenstiel skin incision with firmness extending to the mons pubis (Figure 1) . No erythema, exudate or drainage was observed. Computed tomography of the chest, abdomen and pelvis demonstrated the heterogeneous abdominal mass that measured 12 Â 8 Â 9 cm abutting, but not invading, the uterus, as well as bilateral inguinal and external iliac lymphadenopathy (Figure 2) .
In an effort to balance the risks of prematurity with those of an aggressive malignant lesion, delivery was planned at 34-week gestation. The patient underwent repeat cesarean delivery, wide tumor excision including bilateral pelvic and inguinal lymphadenectomy, and anterior abdominal wall reconstruction. A vigorous male infant was delivered with Apgar scores of 9 and 9 at 1 and 5 min, respectively. A 20 Â 15 cm en block specimen was resected, but fascial and pubic symphysis involvement prevented attainment of disease-free margins.
Final pathology revealed a poorly differentiated cutaneous melanoma spanning the entire dermis and extensively involving the subcutaneous tissue consistent with stage 4 (T4aN2bM1a) disease. There were areas of continuity with the epidermis whereby the cells exhibited a more epithelioid appearance with foci of pagetoid ascent. The tumor cells were S-100 and p-glycoprotein positive, although they failed to show immunoreactivity with Melan A and HMB45 (Figures 3). Given that she had no known primary tumor elsewhere and that there were areas compatible with melanoma in situ on histology, it was assumed that the melanoma arose from the site of the previous cesarean skin scar. Thirteen lymph nodes were negative for malignancy. Placental pathology revealed no metastatic involvement.
The patient's postoperative course was complicated by pneumonia, requiring antibiotics. She was discharged home on postoperative day 9. She was treated with local radiation postoperatively, but developed metastases to her lungs and bones. She participated in a clinical trial with abraxane, temozolomide and genasense with a partial response. She was subsequently treated with carboplatin, which failed to limit disease progression. She died B1 year after diagnosis.
Comments
The diagnosis of malignant melanoma in African-Americans may be delayed, especially when related to skin scars. Inadequate patient education, limited access to medical care and occurrence of disease in non-sun-exposed skin surfaces contribute to this delay. 2 As a result, African-American patients with melanoma are typically diagnosed at advanced stages associated with worse prognoses. From 1996 to 2004, the 5-year survival rates for melanoma was 94.2% for Caucasian women compared with 79.7% for AfricanAmerican women. 7 Unlike Caucasians who generally develop melanoma on sunexposed skin surfaces, African-Americans are more likely to present with melanoma on mucosal and acral sites. 8 Although several case series describe melanocytic lesions on patients' trunks, to our knowledge this is the first report of melanoma arising from a cesarean delivery skin scar.
The role of the altered hormonal milieu during pregnancy on melanoma incidence and progression has been a matter of debate for more than 50 years. In a recent pooled analysis of 10 casecontrol studies, which included 5590 women, there was no association between melanoma incidence and pregnancy. 9 Using the random effects model, the pooled data found no association between pregnancy and the incidence of melanoma (OR 0.95, 95% CI 0.67 to 1.35). 9 The largest population-based study attempting to elucidate the effect of pregnancy on progression of melanoma also illustrated no difference. 3 Contradictory studies suggest an increased incidence of malignant transformation of pre-existing nevi during pregnancy as well as a tendency toward a more aggressive clinical course during pregnancy. 1 Although most of these studies are older uncontrolled studies, this issue remains controversial. This is especially true as more basic research delves into the hormonal milieu of pregnancy and its effects on dysplastic nevi. 2, 4, 5 These studies, plus the observation that hyperpigmentation in several skin areas is normal during pregnancy, continue to fuel this debate. 5 Regardless of patients' race or pregnancy status, certain features of skin lesions may signify ensuing neoplasia. Asymmetric color changes, rapid enlargement over a short time period, location in non-traumatized areas, severe pain and evidence of tissue breakdown and necrosis should prompt a biopsy. When some of these features are present, biopsy should be performed regardless of timing in pregnancy and without delay. Prompt diagnosis and initiation of treatment at earlier disease stages may impact outcomes. Earlier diagnosis may also give patients the opportunity to terminate a pregnancy and pursue treatment options if desired.
